Journal of Capital Medical University ›› 2013, Vol. 34 ›› Issue (6): 830-834.doi: 10.3969/j.issn.1006-7795.2013.06.010

Previous Articles     Next Articles

A method for evaluation of α-synuclein oligomer formation in plasma of patients with Parkinson’s disease

LI Xin1,2, YANG Weiwei1,2, LI Yan1,2, YU Shun1,2   

  1. 1. Department of Neurobiology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China;
    2. Beijing Geriatric Medical and Clinical Center, Beijing 100053, China
  • Received:2013-10-18 Online:2013-12-21 Published:2013-12-13
  • Supported by:

    This study was supported by the National Natural Science Foundation of China(81071014);National Basic Research and Development Program of China(2011CB504101);Capital Health Research and Development Project(SHOUFA 2011-1001-01);National Science and Technology Support Program(2012BAI10B03);Natural Science Foundation of Beijing(7102076).

Abstract:

Objective To establish a method for evaluation of exogenous α-synuclein(α-Syn) oligomer formation in plasma of patients with Parkinson's disease(PD). Methods An ELISA method was developed by using the 3D5 mouse anti-human α-Syn monoclonal antibody. Various concentrations of α-Syn(200, 100, 50, 25, 12.5 μmol/L) was incubated(37℃, 280 r/min) in PD and control sera for 24, 48, 72, and 96 h. The amounts of α-Syn oligomers formed in the sera were measured using the established ELISA method. Results The ELISA method established specifically detected α-Syn oligmers with no reaction to α-Syn monomers. The best differentiation between the α-Syn oligomer formation in PD and control sera was observed when the recombinant α-Syn concentration was 100 μmol/L, with the incubation time being 48 h and the plasma diluted to less than 1/3. Conclusion A method for evaluation of α-Syn oligomer formation in the sera of PD patients and normal controls was established, which can differentiate the potential pathological changes of PD.

Key words: Parkinson’s disease, α-synuclein, plasma, oligomer

CLC Number: